CANNAPHARMARX, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CANNAPHARMARX, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $820.1K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Apr 10, 2025 |
| FY2022 | Dec 31, 2022 | $0 | Sep 1, 2023 |
| FY2022 | Dec 31, 2021 | $0 | Sep 1, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $0 | May 27, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 3, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Sep 14, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.08M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.93M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Apr 10, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.13M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($9.91M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.69M | Apr 10, 2025 |
| FY2022 | Dec 31, 2022 | ($8.53M) | Sep 1, 2023 |
| FY2022 | Dec 31, 2021 | ($8.83M) | Sep 1, 2023 |
| FY2021 | Dec 31, 2020 | ($19.89M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($20.45M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($3.09M) | May 27, 2020 |
| FY2018 | Dec 31, 2017 | ($6.6K) | Apr 3, 2019 |
| FY2018 | Dec 31, 2016 | ($1.00M) | Apr 3, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.35M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.63M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.58M) | Apr 10, 2025 |
| FY2022 | Dec 31, 2022 | ($5.21M) | Sep 1, 2023 |
| FY2022 | Dec 31, 2021 | ($2.99M) | Sep 1, 2023 |
| FY2021 | Dec 31, 2020 | ($14.49M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($15.98M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($954.3K) | May 27, 2020 |
| FY2018 | Dec 31, 2017 | ($6.6K) | Apr 3, 2019 |
| FY2017 | Dec 31, 2016 | ($1.00M) | Sep 14, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $324.1K | Mar 31, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $116.6K | Apr 10, 2025 |
| FY2024 | Dec 31, 2023 | $703.6K | Apr 10, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($789.1K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.70M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($2.27M) | Apr 10, 2025 |
| FY2022 | Dec 31, 2022 | ($1.45M) | Sep 1, 2023 |
| FY2022 | Dec 31, 2021 | ($2.41M) | Sep 1, 2023 |
| FY2021 | Dec 31, 2020 | ($563.6K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($3.79M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($941.1K) | May 27, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 3, 2019 |
| FY2017 | Dec 31, 2016 | ($22.4K) | Sep 14, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.5K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $80.6K | Apr 10, 2025 |
| FY2019 | Dec 31, 2019 | $4.8K | May 27, 2020 |
| FY2019 | Dec 31, 2018 | $0 | May 27, 2020 |
| FY2016 | Dec 31, 2016 | $0 | Sep 14, 2018 |
| FY2016 | Dec 31, 2015 | $2.1K | Sep 14, 2018 |
| FY2015 | Dec 31, 2014 | $100.7K | Sep 11, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.02M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $10.84M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $11.75M | Apr 10, 2025 |
| FY2022 | Dec 31, 2022 | $5.41M | Sep 1, 2023 |
| FY2022 | Dec 31, 2021 | $114.3K | Sep 1, 2023 |
| FY2021 | Dec 31, 2020 | $8.75M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $16.02M | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $10.10M | May 27, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 3, 2019 |
| FY2017 | Dec 31, 2016 | $1.7K | Sep 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.17M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $30.65M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $23.90M | Apr 10, 2025 |
| FY2022 | Dec 31, 2022 | $22.76M | Sep 1, 2023 |
| FY2022 | Dec 31, 2021 | $13.04M | Sep 1, 2023 |
| FY2021 | Dec 31, 2020 | $17.55M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $11.16M | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $10.38M | May 27, 2020 |
| FY2018 | Dec 31, 2017 | $964.3K | Apr 3, 2019 |
| FY2017 | Dec 31, 2016 | $959.3K | Sep 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($30.15M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($19.81M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($12.15M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $17.34M | Apr 10, 2025 |
| FY2022 | Dec 31, 2021 | ($12.93M) | Sep 1, 2023 |
| FY2022 | Dec 31, 2020 | ($8.80M) | Sep 1, 2023 |
| FY2021 | Dec 31, 2019 | $4.85M | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | ($286.3K) | Apr 14, 2021 |
| FY2019 | Dec 31, 2017 | ($964.3K) | May 27, 2020 |
| FY2018 | Dec 31, 2016 | ($957.7K) | Apr 3, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Apr 14, 2021 |
| FY2020 | Dec 31, 2019 | $6.37M | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $6.07M | May 27, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($112.32M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($101.18M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($91.28M) | Apr 10, 2025 |
| FY2022 | Dec 31, 2022 | ($94.70M) | Sep 1, 2023 |
| FY2022 | Dec 31, 2021 | ($86.16M) | Sep 1, 2023 |
| FY2021 | Dec 31, 2020 | ($77.33M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($57.44M) | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | ($36.99M) | May 27, 2020 |
| FY2018 | Dec 31, 2017 | ($33.90M) | Apr 3, 2019 |
| FY2017 | Dec 31, 2016 | ($33.89M) | Sep 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.8K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.2K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $650 | Apr 10, 2025 |
| FY2022 | Dec 31, 2022 | $2.3K | Sep 1, 2023 |
| FY2022 | Dec 31, 2021 | $27.8K | Sep 1, 2023 |
| FY2021 | Dec 31, 2020 | $335.0K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.5K | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | $464.1K | May 27, 2020 |
| FY2017 | Dec 31, 2017 | $0 | Sep 14, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Sep 14, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 0 | Sep 1, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Sep 1, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 10, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Sep 1, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Sep 1, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 662.50M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 662.50M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 440.75M | Apr 10, 2025 |
| FY2022 | Dec 31, 2022 | 274.12M | Sep 1, 2023 |
| FY2022 | Dec 31, 2021 | 125.51M | Sep 1, 2023 |
| FY2021 | Dec 31, 2020 | 46.99M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 36.49M | Apr 14, 2021 |
| FY2019 | Dec 31, 2018 | 18.94M | May 27, 2020 |
| FY2018 | Dec 31, 2017 | 17.96M | Apr 3, 2019 |
| FY2017 | Dec 31, 2016 | 17.96M | Sep 14, 2018 |